ArticleFrontiers in immunology2026
Circulating long non-coding RNAs as diagnostic markers of lupus nephritis and 5-year follow-up disease flares.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Emerging evidence underscores the pivotal role of long non-coding RNAs (lncRNAs) as epigenetic regulators in the immunopathogenesis of systemic lupus erythematosus (SLE). There is a paucity of comprehensive studies that investigate lncRNA associated with lupus nephritis (LN) and disease flares. Thus, we aimed to identify a specific circulating lncRNA panel with high diagnostic accuracy of LN and predictive power of disease flare incidence. Methods: To investigate the feasibility of early diagnosis of LN and disease flares, we examined lncRNAs present in plasma obtained from patients with SLE ( Results: From the ncRNA sequencing results, we identified 9,155 circulating lncRNAs and 148 differentially expressed between patients with SLE and CNT. Seven of these lncRNAs (AL139317.5, AC019080.1, LINC02185, LINC00708, AC239868.1, AC087392.4, and LATS2-AS1) presented statistically significant high expression for the discrimination of the LN (AUC ≥ 0.90), along with high specificity and positive predictive values (≥80%). A panel combining the 7-lncRNA gave an AUC that improved the read count of the single lncRNAs (1.000, Conclusions: We identified, for the first time, a specific lncRNA expression profile associated with renal damage and an increased incidence of 5-year follow-up disease flares in patients with SLE, being excellent predictive biomarkers for disease activity and organ damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.